Structure Therapeutics (GPCR) Income from Continuing Operations (2022 - 2026)
Structure Therapeutics (GPCR) recorded quarterly Income from Continuing Operations of 75968000.0 in Q1 2026, down 142.9% quarter-over-quarter from 177081000.0 in Q4 2025, and down 62.21% on a YoY basis from 201028892.76 in Q1 2025.
Structure Therapeutics (GPCR) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Structure Therapeutics' Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 75968000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 62.21% year-over-year to 75968000.0; the TTM figure through Mar 2026 stood at 26260000.0 (up 80.43% YoY), while the FY2025 annual figure was 2875000.0, up 102.53% from the prior year.
- Income from Continuing Operations was 75968000.0 for Q1 2026 at Structure Therapeutics, down from 177081000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 177081000.0 in Q4 2025 to a low of 75968000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 14146823.53 across 5 years, with a median of 23862000.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations jumped 1247.36% in 2023, then tumbled 149.4% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 4829000.0 in 2022, then surged by 1247.36% to 55406000.0 in 2023, then sank by 149.4% to 27370000.0 in 2024, then surged by 746.99% to 177081000.0 in 2025, then plunged by 142.9% to 75968000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 75968000.0 (Q1 2026), 177081000.0 (Q4 2025), and 65712000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Structure Therapeutics | 9.35 Bn | 9.35 Bn | - | -75.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -75.97 Mn |
| Dec 31, 2025 | 177.08 Mn |
| Sep 30, 2025 | -65.71 Mn |
| Jun 30, 2025 | -61.66 Mn |
| Mar 31, 2025 | -46.83 Mn |
| Dec 31, 2024 | -27.37 Mn |
| Sep 30, 2024 | -33.98 Mn |
| Jun 30, 2024 | -26.03 Mn |
| Mar 31, 2024 | -26.04 Mn |
| Dec 31, 2023 | 55.41 Mn |
| Sep 30, 2023 | -23.86 Mn |
| Jun 30, 2023 | -23.28 Mn |
| Mar 31, 2023 | -17.98 Mn |
| Dec 31, 2022 | -4.83 Mn |
| Sep 30, 2022 | -12.42 Mn |
| Jun 30, 2022 | -13.95 Mn |
| Mar 31, 2022 | -13.08 Mn |